Home / CLRB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CLRB make money? Does CLRB have pricing power? What's the Earnings Whisper? Will CLRB profit more as the business scales? What is CLRB's management track record? Is CLRB's current price justified?

Cellectar Biosciences, Inc.

$2.31 -$1.16 (-33.43%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$2.37

Day Range

$2.31$2.38

Year Range

$2.2$6.52

Market Cap

18.46M

AVG Volume

1.07M

Trailing/Forward PE

-0.51/-

PEG ratio

0.02

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD) · TTM

CLRB Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-22.32M
26 Q1	-20.84M
25 Q4	-21.79M
25 Q3	-18.85M
25 Q2	-29.07M
25 Q1	-24.54M
24 Q4	-44.58M
24 Q3	-50.11M
24 Q2	-52.96M
24 Q1	-62.22M

Operating Income (USD) · TTM

CLRB Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-23.53M
26 Q1	-22.37M
25 Q4	-22.98M
25 Q3	-30.03M
25 Q2	-38.51M
25 Q1	-46.18M
24 Q4	-51.78M
24 Q3	-51.58M
24 Q2	-47.67M
24 Q1	-42.26M

EBITDA (USD) · TTM

CLRB EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-22.33M
26 Q1	-20.79M
25 Q4	-21.58M
25 Q3	-18.55M
25 Q2	-28.76M
25 Q1	-24.22M
24 Q4	-44.22M
24 Q3	-49.87M
24 Q2	-52.76M
24 Q1	-62.04M

Cash Flows (USD) · TTM

CLRB Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-19.48M
26 Q1	-18.59M
25 Q4	-23.12M
25 Q3	-29.75M
25 Q2	-34.64M
25 Q1	-43.69M
24 Q4	-47.69M
24 Q3	-46.57M
24 Q2	-46.07M
24 Q1	-39.44M

EPS (USD) · TTM

CLRB EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-4.56
26 Q1	-7.38
25 Q4	-10.35
25 Q3	-10.78
25 Q2	-20.55
25 Q1	-22.59
24 Q4	-45.53
24 Q3	-56.02
24 Q2	-91.32
24 Q1	-113

Expenses (USD) · TTM

CLRB Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	23.65M
26 Q1	22.49M
25 Q4	22.99M
25 Q3	30.1M
25 Q2	38.57M
25 Q1	46.26M
24 Q4	51.88M
24 Q3	51.89M
24 Q2	48.57M
24 Q1	43.14M

Shares Outstanding · TTM

CLRB Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	-428.31K
26 Q1	-565.39K
25 Q4	-1.13M
25 Q3	-2.61M
25 Q2	-4.15M
25 Q1	-3.58M
24 Q4	-3.47M
24 Q3	-1.99M
24 Q2	-952.24K
24 Q1	-1.37M

Employee Count

CLRB Employee Count by quarter
Period	Employee Count
2025	11
2024	11
2023	20
2022	15
2021	12
2020	11
2019	8
2018	7
2017	15
2016	15

Free Cash Flow Yield

CLRB Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-68.96%
Sep 26	-67.21%
Aug 26	-62.96%
Aug 26	-61.5%
Aug 26	-61.27%
Aug 26	-170.59%
Jul 26	-170.59%
Jul 26	-181.92%
Jul 26	-174.67%
Jul 26	-155.47%
Jul 26	-156.02%
Jun 26	-173.98%
Jun 26	-157.14%
Jun 26	-196.6%
Jun 26	-169.27%
May 26	-139.62%
May 26	-137.01%
May 26	-141.88%
May 26	-175.92%
May 26	-202.74%
Apr 26	-197.6%
Apr 26	-186.77%
Apr 26	-197.6%
Apr 26	-213.87%
Mar 26	-201.99%
Mar 26	-168.32%
Mar 26	-170.43%
Mar 26	-197.6%
Feb 26	-289.48%
Feb 26	-278.35%
Feb 26	-285.96%
Feb 26	-309.48%
Jan 26	-292.18%
Jan 26	-248.24%
Jan 26	-262.06%
Jan 26	-305.46%
Jan 26	-271.13%
Dec 25	-367.5%
Dec 25	-351.05%
Dec 25	-259.89%
Dec 25	-249.55%
Nov 25	-262.06%
Nov 25	-328.96%
Nov 25	-324.42%
Nov 25	-635.16%
Oct 25	-635.16%
Oct 25	-538.3%
Oct 25	-478.49%
Oct 25	-464.05%
Oct 25	-372.53%
Sep 25	-390.07%
Sep 25	-414.08%
Sep 25	-423.86%
Sep 25	-432.37%
Aug 25	-442.13%
Aug 25	-441.23%
Aug 25	-496.13%
Aug 25	-601.32%
Aug 25	-602.59%
Jul 25	-558.79%
Jul 25	-569.99%
Jul 25	-582.84%
Jul 25	-592.55%
Jun 25	-360.03%
Jun 25	-325.06%
Jun 25	-229.37%
Jun 25	-262.87%
May 25	-371.8%
May 25	-380.75%
May 25	-386.97%
May 25	-460.05%
May 25	-420.39%
Apr 25	-367.05%
Apr 25	-380.55%
Apr 25	-407.34%
Apr 25	-430.46%
Mar 25	-339.99%
Mar 25	-308.36%
Mar 25	-360.46%
Mar 25	-372.34%
Feb 25	-409.23%
Feb 25	-380.31%
Feb 25	-407.35%
Feb 25	-394.68%
Jan 25	-471.1%
Jan 25	-457.74%
Jan 25	-485.92%
Jan 25	-419.37%
Jan 25	-342.87%
Dec 24	-383.6%
Dec 24	-503.84%
Dec 24	-455.4%
Dec 24	-85.18%
Nov 24	-76.89%
Nov 24	-74.94%
Nov 24	-488.57%
Nov 24	-428.65%
Nov 24	-447.66%
Oct 24	-66.2%
Oct 24	-64.3%

Price to Book

CLRB Price to Book by quarter
Period	Price to Book
Sep 26	0.95
Sep 26	0.97
Aug 26	1.04
Aug 26	1.06
Aug 26	1.06
Aug 26	2.31
Jul 26	2.31
Jul 26	2.17
Jul 26	2.26
Jul 26	2.53
Jul 26	2.53
Jun 26	2.27
Jun 26	2.51
Jun 26	2
Jun 26	2.33
May 26	2.82
May 26	2.88
May 26	2.78
May 26	1.33
May 26	1.15
Apr 26	1.18
Apr 26	1.25
Apr 26	1.18
Apr 26	1.09
Mar 26	1.15
Mar 26	1.38
Mar 26	1.37
Mar 26	1.18
Feb 26	1.1
Feb 26	1.14
Feb 26	1.11
Feb 26	1.02
Jan 26	1.09
Jan 26	1.28
Jan 26	1.21
Jan 26	1.04
Jan 26	1.17
Dec 25	0.86
Dec 25	0.9
Dec 25	1.22
Dec 25	1.27
Nov 25	1.21
Nov 25	0.96
Nov 25	0.98
Nov 25	0.73
Oct 25	0.73
Oct 25	0.86
Oct 25	0.97
Oct 25	1
Oct 25	1.25
Sep 25	1.19
Sep 25	1.12
Sep 25	1.09
Sep 25	1.07
Aug 25	1.05
Aug 25	1.05
Aug 25	0.94
Aug 25	0.88
Aug 25	0.88
Jul 25	0.95
Jul 25	0.93
Jul 25	0.91
Jul 25	0.89
Jun 25	1.47
Jun 25	1.63
Jun 25	2.31
Jun 25	2.01
May 25	1.42
May 25	1.39
May 25	1.37
May 25	0.73
May 25	0.79
Apr 25	0.91
Apr 25	0.88
Apr 25	0.82
Apr 25	0.77
Mar 25	0.98
Mar 25	1.08
Mar 25	0.93
Mar 25	0.82
Feb 25	0.75
Feb 25	0.81
Feb 25	0.75
Feb 25	0.78
Jan 25	0.65
Jan 25	0.67
Jan 25	0.63
Jan 25	0.73
Jan 25	0.9
Dec 24	0.8
Dec 24	0.61
Dec 24	0.67
Dec 24	3.61
Nov 24	3.99
Nov 24	4.1
Nov 24	0.69
Nov 24	0.78
Nov 24	0.75
Oct 24	4.29
Oct 24	4.42

No video analysis for this stock yet. Request one from our team.

News: CLRB

seekingalpha.com · 18 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript

seekingalpha.com · 13 Aug 2026

Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript

globenewswire.com · 13 Aug 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program

defenseworld.net · 11 Aug 2026

Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00

Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on

globenewswire.com · 30 Jul 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m.

globenewswire.com · 15 Jul 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma